Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone
Robert G Micheletti, Christian Pagnoux, Roy N Tamura, Peter C Grayson, Carol A McAlear, Renee Borchin, Jeffrey P Krischer, Peter A Merkel, Vasculitis Clinical Research Consortium, Robert G Micheletti, Christian Pagnoux, Roy N Tamura, Peter C Grayson, Carol A McAlear, Renee Borchin, Jeffrey P Krischer, Peter A Merkel, Vasculitis Clinical Research Consortium
Abstract
Background: Skin-limited forms of vasculitis, while lacking systemic manifestations, can persist or recur indefinitely, cause pain, itch, or ulceration, and be complicated by infection or scarring. High-quality evidence on how to treat these conditions is lacking. The aim of this comparative effectiveness study is to determine the optimal management of patients with chronic skin-limited vasculitis.
Methods: ARAMIS is a multicenter, sequential, multiple assignment randomized trial with an enrichment design (SMARTER) aimed at comparing the efficacy of three drugs-azathioprine, colchicine, and dapsone-commonly used to treat various forms of isolated skin vasculitis. ARAMIS will enroll patients with isolated cutaneous small or medium vessel vasculitis, including cutaneous small vessel vasculitis, immunoglobulin A (IgA) vasculitis (skin-limited Henoch-Schönlein purpura), and cutaneous polyarteritis nodosa. Patients not responding to the initial assigned therapy will be re-randomized to one of the remaining two study drugs (Stage 2). Those with intolerance or contraindication to a study drug can be randomized directly into Stage 2. Target enrollment is 90 participants, recruited from international centers affiliated with the Vasculitis Clinical Research Consortium. The number of patients enrolled directly into Stage 2 of the study will be capped at 10% of the total recruitment target. The primary study endpoint is the proportion of participants from the pooled study stages with a response to therapy at month 6, according to the study definition.
Discussion: ARAMIS will help identify effective agents for skin-limited forms of vasculitis, an understudied group of diseases. The SMARTER design may serve as an example for future trials in rare diseases.
Trial registration: ClinicalTrials.gov: NCT02939573. Registered on 18 October 2016.
Keywords: Azathioprine; Colchicine; Dapsone; Sequential multiple assignment randomized trial; Skin vasculitis.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
References
- Callen JP. Cutaneous vasculitis: what have we learned in the past 20 years? Arch Dermatol. 1998;134(3):355–357. doi: 10.1001/archderm.134.3.355.
- Callen JP. A clinical approach to the vasculitis patient in the dermatologic office. Clin Dermatol. 1999;17(5):549–553. doi: 10.1016/S0738-081X(99)00074-7.
- Carlson JA, Chen KR. Cutaneous vasculitis update: neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes. Am J Dermatopathol. 2007;29(1):32–43. doi: 10.1097/01.dad.0000245198.80847.ff.
- Chen KR, Carlson JA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol. 2008;9(2):71–92. doi: 10.2165/00128071-200809020-00001.
- Sais G, Vidaller A, Jucgla A, Gallardo F, Peyri J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol. 1995;131(12):1399–1402. doi: 10.1001/archderm.1995.01690240061009.
- Gibson LE. Cutaneous vasculitis update. Dermatol Clin. 2001;19(4):603–615. doi: 10.1016/S0733-8635(05)70303-X.
- Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM. Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol. 2005;17(1):56–61.
- Pina T, Blanco R, Gonzalez-Gay MA. Cutaneous vasculitis: a rheumatologist perspective. Curr Allergy Asthma Rep. 2013;13(5):545–554. doi: 10.1007/s11882-013-0367-7.
- Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231–236. doi: 10.1016/j.det.2011.11.003.
- Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707–713. doi: 10.1111/1523-1747.ep12365600.
- Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Thiopurinemethyltransferase (TPMT) genotype and TPMT activity in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: relation to azathioprine maintenance treatment and adverse effects. Ann Rheum Dis. 2009;68(5):758–759. doi: 10.1136/ard.2008.097667.
- Jabin D, Kumar S, Gow PJ. Outcome of patients on azathioprine: a need for a better pre-treatment assessment and dosing guideline. N Z Med J. 2010;123(1324):67–73.
- Tamura RN, Krischer JP, Pagnoux C, Micheletti R, Grayson PC, Chen YF, et al. A small n sequential multiple assignment randomized trial design for use in rare disease research. Contemp Clin Trials. 2016;46:48–51. doi: 10.1016/j.cct.2015.11.010.
Source: PubMed